CurifyLabs receives 6.7 million euros for automated production of personalized medicines

CurifyLabs is developing a technology for the automated production of patient-specific medicines. Now the startup receives new funding to scale up and expand the market

Helsinki, May 27, 2025 - Finnish company CurifyLabs has closed a €6.7 million financing round to automate the production of compounded medications. The round was led by the Finnish growth financier Springvest. In addition, CurifyLabs will receive deep-tech financing of 1 million euros from Business Finland.

The capital will be used to scale production, expand the market and acquire major customers. A particular focus is on the US market, where, according to the company, the majority of the world's individualized medicines are produced.

Why compounding is important

Customized medicines are always used when standard preparations are not suitable. Reasons for this can include individual dosage requirements, allergies, age-related restrictions or supply bottlenecks. Compounding is often the only option for customized medication, especially for children or cancer patients.

Even in modern pharmacies, the manual production of personalized medication is time-consuming, error-prone and expensive. Our goal is to fundamentally improve this process - so that every patient gets the treatment they really need.

Charlotta Topelius, CEO and co-founder of CurifyLabs

According to CurifyLabs, the market is growing at around 5.5% per year. Despite the growing demand, only around 1 % of all medications are individually tailored to patients. The main reasons for this are the complexity and time required for manual production.

Technology for the automation of medication production

Together with pharmacists and based on ten years of research, CurifyLabs has developed a solution that automates and standardizes the production of individualized medicines. The so-called Compounding System Solution comprises both formulation software and the hardware and software unit known as the "Pharma Printer", which can be used to produce liquid or solid medicines such as tablets.

The central components are

• High-quality carriers (excipients), which are combined with active ingredients,
• automated dosing and formulation by the printer,
• a cloud-based formulation library with validated processes,
• integrated quality assurance to prevent errors.

According to the company, production can be up to four times faster than by manual means - with greater safety and reproducibility at the same time.

New EU project "RoboPharma" launched

Alongside the financing round, CurifyLabs announced the launch of the EU project "RoboPharma". The aim of the €5.6 million project is to develop an AI- and robotics-based platform for decentralized pharmaceutical production. The project is funded by the EU4Health program.

RoboPharma is primarily intended to improve the crisis resilience of European healthcare systems. In collaboration with six European partners, CurifyLabs aims to develop a scalable solution for pharmacies and hospitals to produce medicines safely and efficiently on site - for example in the event of supply bottlenecks or emergency situations.

CurifyLabs addresses key challenges in pharmaceutical supply. In view of a globally growing compounding market, the solution offers enormous potential - both medically and economically.

Aki Soudunsaari, CEO of the investor Springvest

CurifyLabs has raised 17.6 million euros in capital to date and is active in Germany and the USA in addition to its headquarters in Helsinki. CTO and co-founder Niklas Sandler is Professor of Pharmaceutical Technology at Åbo Akademi University. The team has many years of experience in the pharmaceutical industry and in the healthtech sector.